Since the onset of the crisis, the South Centre has argued that policy responses to the crisis by the European Union and the United States has suffered from serious shortcomings that would delay recovery and entail unnecessary losses of income and jobs, and also endanger future growth and stability.
The United Nations is on the verge of releasing a new set of Sustainable Development Goals (SDGs) - perhaps 17 or more - to replace the eight Millennium Development Goals (MDGs) which will run out by the end of 2015.
The growing crisis of antibiotic resistance is catching the attention of policy-makers, but not at a fast enough rate to tackle it. More diseases are affected by resistance, meaning the bacteria cannot be killed even if different drugs are used on some patients, who then succumb.
A fight taking place in the World Trade Organisation (WTO) negotiations towards the Bali Ministerial Conference shows how the rules on agriculture allow developed countries to continue to shell out huge subsidies while penalising farmers in developing countries.
As world leaders from 193 countries evaluate the successes and failures of the Millennium Development Goals (MDGs) during high-level meetings and special events here, the United Nations claims that extreme poverty worldwide has been cut in half.
Two new trade agreements involving the two economic giants, the United States and the European Union, are leading a charge against the role of the state in the economy of developing countries.
The current discourse on Global Value Chains by key proponents and also the World Trade Organisation (WTO) secretariat is that developing countries should liberalise - in goods and services - and conclude a trade facilitation agreement.
The rise of the "global middle class" is widely attributed to the gradual eradication of extreme poverty in the developing world, even as the United Nations says that millions of people in countries such as India, China and Brazil have graduated from the ranks of the indigent.
India’s refusal to grant patent protection for the anti-cancer drug Glivec, developed by Swiss drugmaker Novartis, is a victory for the developing world, which depends on low-cost exports of generic medicines from the Asian giant, said public health specialist Germán Velásquez.